3 October 2017Americas

FDA issues new guidance to boost generic competition

The US Food and Drug Administration (FDA) has issued new guidance as part of its bid to target the barriers to generic drug competition.

Already registered?

Login to your account

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

FDA targets barriers to generic competition

26 June 2017 The Food and Drug Administration has announced its intention to target the barriers to generic drug competition.

FDA to increase drug competition and speed up ANDA reviews

28 June 2017 The US Food and Drug Administration has revealed plans to increase competition in the US market for prescription drugs, as well as to facilitate the entry of generic drugs into the market.

FDA reveals further steps to encourage generic competition

3 January 2018 The US Food and Drug Administration revealed additional steps aimed at encouraging generic competition today.

More on this story

FDA targets barriers to generic competition

26 June 2017 The Food and Drug Administration has announced its intention to target the barriers to generic drug competition.

FDA to increase drug competition and speed up ANDA reviews

28 June 2017 The US Food and Drug Administration has revealed plans to increase competition in the US market for prescription drugs, as well as to facilitate the entry of generic drugs into the market.

FDA reveals further steps to encourage generic competition

3 January 2018 The US Food and Drug Administration revealed additional steps aimed at encouraging generic competition today.

More on this story

FDA targets barriers to generic competition

26 June 2017 The Food and Drug Administration has announced its intention to target the barriers to generic drug competition.

FDA to increase drug competition and speed up ANDA reviews

28 June 2017 The US Food and Drug Administration has revealed plans to increase competition in the US market for prescription drugs, as well as to facilitate the entry of generic drugs into the market.

FDA reveals further steps to encourage generic competition

3 January 2018 The US Food and Drug Administration revealed additional steps aimed at encouraging generic competition today.

More features

President Trump 2.0: Five major areas to watch

Startup CFO’s betrayal is a lesson in preparing for the worst

Sandoz lands reduced antitrust award of $70m

New president’s to-do list: Patent bills, non-competes, USPTO director?

Sanofi subsidiary fends off $450m trade secrets case

Regulatory expert joins White & Case

Teva faces $500m fine for antitrust breaches over MS drug

UK Budget: A missed opportunity?